IHS Chemical Week

Regions :: North Asia :: Korea

Merck & Co. and Hanwha Chemical to Develop Biosimilar Candidate

12:03 AM MDT | June 14, 2011 | Deepti Ramesh

Merck & Co. (Whitehouse Station, NJ) says it has entered into an exclusive global agreement with Hanwha Chemical (Seoul) to develop and commercialize a candidate biosimilar form of Enbrel (etanercept). Hanwha Chemical, through its Bio business unit, and Merck, through a subsidiary, will work together to develop and commercialize HD203, a candidate biosimilar form of etanercept developed by Hanwha, under the terms of the agreement. Merck will conduct clinical development and be responsible for manufacturing. Merck will commercialize HD203 globally, except for...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa